Economic evaluation in the field of mental health: conceptual basis.
暂无分享,去创建一个
[1] Aman Khan. [Cost analysis]. , 2022, ZWR.
[2] C. Asseburg,et al. Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model , 2012, PloS one.
[3] Morgan E. Lim,et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application , 2011, ClinicoEconomics and outcomes research : CEOR.
[4] M. Ferraz,et al. Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. , 2011, Revista de saude publica.
[5] J. Brazier,et al. Estimating the SF-6D value set for a population-based sample of Brazilians. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[6] M. Ferraz,et al. Cost-Effectiveness of Home Visits in the Outpatient Treatment of Patients with Alcohol Dependence , 2009, European Addiction Research.
[7] L. Lindner,et al. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. , 2009, Revista de saude publica.
[8] L. Lindner,et al. Evaluación económica del tratamiento de la esquizofrenia con antipsicóticos en Sistema Único de Salud , 2009 .
[9] David McDaid,et al. Is it worth investing in mental health promotion and prevention of mental illness? A systematic review of the evidence from economic evaluations , 2008, BMC public health.
[10] L. Salvador-Carulla,et al. Implementing mental health economic evaluation evidence: Building a bridge between theory and practice , 2007 .
[11] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[12] M. Drummond,et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. , 2006, Health technology assessment.
[13] M. Ferraz,et al. Cost of schizophrenia: direct costs and use of resources in the State of São Paulo. , 2006, Revista de saude publica.
[14] J. Ayuso-Mateos,et al. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder , 2005, British Journal of Psychiatry.
[15] J. Rehm,et al. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. , 2004, Journal of studies on alcohol.
[16] J. Ayuso-Mateos,et al. Reducing the global burden of depression , 2004, British Journal of Psychiatry.
[17] M Sculpher,et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.
[18] Rob Baltussen,et al. Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2003 .
[19] David McDaid,et al. Because It's Worth It: A Practical Guide to Conducting Economic Evaluations in the Social Welfare Field , 2003 .
[20] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[21] D. Feeny,et al. The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.
[22] S. Evers,et al. Economic evaluation of mental health care interventions. A review. , 1997, Health economics.
[23] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[24] Diana B. Petitti,et al. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .
[25] G W Torrance,et al. Incorporating Utility-Based Quality-of-Life Assessment Measures in Clinical Trials: Two Examples , 1989, Medical care.
[26] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[27] Julian Perelman. Avaliação económica em saúde , 2014 .
[28] T. Einarson,et al. The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary , 2012, PharmacoEconomics.
[29] K. Roberts. Foresight mental capital and wellbeing project , 2010 .
[30] 40026386 Return Undeliverable,et al. Canadian Agency for Drugs and Technologies in Health , 2009 .
[31] Peter Muennig,et al. Cost-effectiveness analyses in health : a practical approach , 2008 .
[32] L. Salvador-Carulla,et al. Cost-effectiveness and mental health , 2008 .
[33] M. Severn,et al. Canadian Agency for Drugs and Technologies in Health Effectiveness of magnetic resonance imaging ( MRI ) screening for women at high risk of breast cancer , 2007 .
[34] C. Normand,et al. A systematic review of the role of bisphosphonates in metastatic disease. , 2004, Health technology assessment.
[35] N. Waugh,et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. , 2001, Health technology assessment.
[36] J Beecham,et al. A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression. , 2000, Health technology assessment.
[37] R. Koff,et al. Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine , 1995 .
[38] Martin Knapp,et al. Costing psychiatric interventions. , 1992 .
[39] C. Brewin,et al. Measuring mental health needs , 1992 .
[40] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[41] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .